TCRX Tscan Therapeutics Inc
Company Analysis
Latest News
🔴 Tscan Therapeutics is trading 5.4% down in pre-market amid elevated Treasury yields
Tscan Therapeutics is trading 5.42% down now at $0.78 as broader risk-off pressure weighs on growth-oriented stocks. - No new company-specific announcement,...
🔴 Tscan Therapeutics is trading 5.53% down in after-hours trading as rising Treasury yields pressure growth stocks
Tscan Therapeutics is trading 5.53% down now at $0.78 as broad risk-off selling pressures U.S. equities on August 18, 2026. - No new company-specific...
🟢 Tscan Therapeutics is trading 5.6% up today despite no clear company-specific catalyst
Tscan Therapeutics is trading at $0.83, up 5.64%, with no clear company-specific announcement, filing, analyst action, or clinical catalyst identified for...
Tscan Therapeutics maintains Buy rating, despite going concern and cash risks
H.C. Wainwright reiterated its Buy rating for Tscan Therapeutics on August 13, 2026. The firm issued this update one day after Tscan released its...
TScan Therapeutics second quarter 2026 loss narrows as pivotal Phase 3 study begins
TScan Therapeutics reported a narrowed net loss of $30.4 million for the second quarter of 2026, primarily driven by a $9.2 million reduction in R&D expenses....
Tscan Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Tscan Therapeutics is expected to report a Q2 2026 loss of $0.29 per share on revenue of $1.88 million, with the stock currently trading at $0.80 against a...
🟢 Tscan Therapeutics is trading 5.2% up today amid a broader biotech rally
Tscan Therapeutics is trading 5.2% up at $0.77 today, appearing to follow a broader bid in the biotech sector and constructive overall market sentiment rather...
🟢 Tscan Therapeutics is trading 3.9% up today after dosing first patient in Phase 3 ALLOHA-2 trial
Tscan Therapeutics is trading 3.9% up at $0.79 today after announcing the first patient dosing of its lead T-cell therapy, TSC-101, in the pivotal Phase 3...
TScan Therapeutics Doses First Phase 3 Patient to Prevent Leukemia Relapse
TScan Therapeutics administered the first dose of its lead T-cell therapy candidate, TSC-101, in the pivotal Phase 3 ALLOHA-2™ clinical trial. The study...
🟢 Tscan Therapeutics is trading 5.1% up today amid a broader market rebound
Tscan Therapeutics is trading at $0.78 (+5.10%) as part of a broader market rebound, with no company-specific announcements, earnings updates, or analyst...
🟢 Tscan Therapeutics is trading 7.9% up today as it rebounds amid broader market strength
Tscan Therapeutics is trading at $0.80 (7.9%) up today, rebounding from a multi-day downtrend amid an improving broader market risk tone. • The pre-market...
🔴 Tscan Therapeutics is trading 5.3% down today amid broader biotech sector pressure
Tscan Therapeutics is trading 5.3% down today at $0.80, extending its recent weakness amid broader sector-driven pressure and risk-off sentiment in biotech and...
🟢 Tscan Therapeutics is trading 6.3% up today after yesterday's sector-driven drop
Tscan Therapeutics is trading at $0.90 (up 6.3%) in pre-market action, rebounding from yesterday’s 5.1% decline to $0.85. • The move appears to be a modest...
🔴 Tscan Therapeutics is trading 5.1% down today amid broad market and biotech sector pressure
Tscan Therapeutics is trading 5.1% down at $0.85 as shares move lower alongside a weak broader market and pressured growth/biotech sentiment. • There are no...
🔴 Tscan Therapeutics is trading 10.0% down
Tscan Therapeutics is trading at $0.93, down 10.0% from a comparison close of $1.03 during regular trading. This is a price-action follow-up, so a separate...
🔴 Tscan Therapeutics is trading 5.1% down today amid sector-wide biotech weakness and profit-taking after recent TSC-101 gains
Tscan Therapeutics is trading at $0.98 (-5.09%) as the biotech group continues to soften alongside broader risk-off sentiment. • No new company-specific...
🟢 Tscan Therapeutics is trading 5.8% up today as it rebounds from a regular-session decline following TSC-101 optimism
Tscan Therapeutics is trading at $1.09, up 5.8% in after-hours trading, as the stock rebounds from a regular-session decline amid ongoing optimism for its...
🔴 Tscan Therapeutics is trading 5.5% down today as recent gains from its TSC-101 program moderate amid sector-wide pressure
Tscan Therapeutics is trading 5.5% down today at $1.03 as recent gains from its TSC-101 program and FDA-aligned phase III plans begin to moderate. • The...
🔴 Tscan Therapeutics is trading 10.3% down
Tscan Therapeutics is trading at $1.13, down 10.3% from a comparison close of $1.26 during regular trading. This is a price-action follow-up, so a separate...
🟢 TCRX makes sharp 10.7% jump
TCRX is trading at $1.19, up 10.7% versus the comparison close of $1.07 during regular trading. This is a price-movement alert; no separate company-specific...